Transthyretin Cardiac Amyloidosis in Older Americans

Journal of Cardiac Failure

Volumn 22, Issue 12, 2016, Pages 996-1003

  Brunjes, Danielle L ^a   Castano, Adam ^a   Clemons, Autumn ^a   Rubin, Jonah ^a   Maurer, Mathew S ^a  

^a Department of Medicine   (United States)

Author keywords

diagnostic strategies; geriatric heart failure; Transthyretin cardiac amyloidosis

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIFLUNISAL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; LOOP DIURETIC AGENT; MONOCLONAL ANTIBODY; PATISIRAN; PLACEBO; PREALBUMIN; PROLINE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; PYROPHOSPHATE TECHNETIUM TC 99M; REVUSIRAN; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; TECHNETIUM PHOSPHATE TC 99M; TOLCAPONE; TORASEMIDE; TROPONIN T;

AGE; AGED; AMERICAN; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; CLINICAL OUTCOME; DRUG EFFICACY; ELECTROCARDIOGRAM; ELECTROPHORESIS; EPIDEMIOLOGICAL DATA; GENE MUTATION; HEART AMYLOIDOSIS; HEART FAILURE; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HEART TRANSPLANTATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM RESTRICTION; TRANSTHYRETIN CARDIAC AMYLOIDOSIS; WILD TYPE; AMYLOID NEUROPATHIES, FAMILIAL; UNITED STATES;

AGED; AMYLOID NEUROPATHIES, FAMILIAL; HUMANS; UNITED STATES;

EID: 84998787338     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2016.10.008     Document Type: Review

References (61)

1. 1 Ruberg, F.L., Berk, J.L., Transthyretin (TTR) cardiac amyloidosis. Circulation 126 (2012), 1286–1300.
2. 2 Westermark, P., Aspects on human amyloid forms and their fibril polypeptides. FEBS J 272 (2005), 5942–5949.
3. 3 Castano, A., Drachman, B.M., Judge, D., Maurer, M.S., Natural history and therapy of TTR–cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20 (2015), 163–178.
4. 4 Pitkanen, P., Westermark, P., Cornwell, G.G. 3rd., Senile systemic amyloidosis. Am J Pathol 117 (1984), 391–399.
5. 5 Dharmarajan, K., Maurer, M.S., Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc 60 (2012), 765–774.
6. 6 Connors, L.H., Sam, F., Skinner, M., Salinaro, F., Sun, F., Ruberg, F.L., et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133 (2016), 282–290.
7. 7 U.S Census Bureau. Current Estimates Data. 2015.
8. 8 Wechalekar, A.D., Gillmore, J.D., Hawkins, P.N., Systemic amyloidosis. Lancet 387 (2016), 2641–2654.
9. 9 Jacobson, D.R., Alexander, A.A., Tagoe, C., Buxbaum, J.N., Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid 22 (2015), 171–174.
10. 10 Tanskanen, M., Peuralinna, T., Polvikoski, T., Notkola, I.L., Sulkava, R., Hardy, J., et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40 (2008), 232–239.
11. 11 Coelho, T., Maurer, M.S., Suhr, O.B., THAOS—the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29 (2013), 63–76.
12. 12 Pinney, J.H., Whelan, C.J., Petrie, A., Dungu, J., Banypersad, S.M., Sattianayagam, P., et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc, 2, 2013, e000098.
13. 13 Givens, R.C., Russo, C., Green, P., Maurer, M.S., Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health 9 (2013), 229–235.
14. 14 González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., de Haro–del Moral, F., Cobo-Marcos, M., Robles, C., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
15. 15 Castano, A., Bokhari, S., Maurer, M.S., Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2595–2597.
16. 16 Maurer, M.S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68 (2016), 161–172.
17. 17 Goodman, D.S., Plasma retinol-binding protein. 1984, Academic Press, Orlando, FL.
18. 18 Buxbaum, J.N., Reixach, N., Transthyretin: the servant of many masters. Cell Mol Life Sci 66 (2009), 3095–3101.
19. 19 Liao, R., Jain, M., Teller, P., Connors, L.H., Ngoy, S., Skinner, M., et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104 (2001), 1594–1597.
20. 20 Bhuiyan, T., Helmke, S., Patel, A.R., Ruberg, F.L., Packman, J., Cheung, K., et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail 4 (2011), 121–128.
21. 21 Ng, B., Connors, L.H., Davidoff, R., Skinner, M., Falk, R.H., Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165 (2005), 1425–1429.
22. 22 Quarta, C.C., Solomon, S.D., Uraizee, I., Kruger, J., Longhi, S., Ferlito, M., et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129 (2014), 1840–1849.
23. 23 Mishra, S., Guan, J., Plovie, E., Seldin, D.C., Connors, L.H., Merlini, G., et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 305 (2013), H95–103.
24. 24 Sekijima, Y., Uchiyama, S., Tojo, K., Sano, K., Shimizu, Y., Imaeda, T., et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 42 (2011), 1785–1791.
25. 25 Westermark, P., Westermark, G.T., Suhr, O.B., Berg, S., Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci 119 (2014), 223–228.
26. 26 Cyrille, N.B., Goldsmith, J., Alvarez, J., Maurer, M.S., Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 114 (2014), 1089–1093.
27. 27 Sperry, B.W., Vranian, M.N., Hachamovitch, R., Joshi, H., Ikram, A., Phelan, D., et al. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc, 5, 2016, e002877.
28. 28 Carroll, J.D., Gaasch, W.H., McAdam, K.P., Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 49 (1982), 9–13.
29. 29 Quarta, C.C., Perlini, S., Longhi, S., Berardini, A., Musca, F., Salinaro, F., et al. A simple voltage/mass index improved diagnsois of cardiac amyloidosis; an electrocardiographic and echocardiographic study of 570 patients with left ventricular hypertrophy. J Am Coll Cardiol, 59, 2012, E1586.
30. 30 Grogan, M.S.C., Kyle, R.A., Zeldenrust, S.R., Gertz, M.A., Lin, G., Klarich, K.W., et al. Natural history of wild type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68 (2016), 1014–1020.
31. 31 Rapezzi, C., Guidalotti, P., Salvi, F., Riva, L., Perugini, E., Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol 51 (2008), 1509–1510 author reply 10.
32. 32 Hutt, D.F., Quigley, A.M., Page, J., Hall, M.L., Burniston, M., Gopaul, D., et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 15 (2014), 1289–1298.
33. 33 Galat, A., Rosso, J., Guellich, A., van der Gucht, A., Rappeneau, S., Bodez, D., et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 22 (2015), 210–220.
34. 34 Bokhari, S., Castano, A., Pozniakoff, T., Deslisle, S., Latif, F., Maurer, M.S., (99m)Tc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6 (2013), 195–201.
35. 35 Gillmore, J.D., Maurer, M.S., Falk, R.H., Merlini, G., Damy, T., Dispenzieri, A., et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133 (2016), 2404–2412.
36. 36 Castano, A., Haq, M., Narotsky, D., Goldsmith, J., Weinberg, R.L., Morgenstern, R., et al. Multicenter experience of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol, 2016.
37. 37 Gertz, M.A., Falk, R.H., Skinner, M., Cohen, A.S., Kyle, R.A., Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol, 55, 1985, 1645.
38. 38 Pollak, A., Falk, R.H., Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104 (1993), 618–620.
39. 39 Cassidy, J.T., Cardiac amyloidosis. Two cases with digitalis sensitivity. Ann Intern Med 55 (1961), 989–994.
40. 40 Pomerance, A., Senile cardiac amyloidosis. Br Heart J 27 (1965), 711–718.
41. 41 Davis, M.K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant 15 (2015), 650–658.
42. 42 Davis, M.K., Lee, P.H., Witteles, R.M., Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 34 (2015), 658–666.
43. 43 Topilsky, Y., Pereira, N.L., Shah, D.K., Boilson, B., Schirger, J.A., Kushwaha, S.S., et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail 4 (2011), 266–275.
44. 44 Grupper, A., Park, S.J., Pereira, N.L., Schettle, S.D., Gerber, Y., Topilsky, Y., et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant 34 (2015), 1042–1049.
45. 45 Berk, J.L., Suhr, O.B., Obici, L., Sekijima, Y., Zeldenrust, S.R., Yamashita, T., et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
46. 46 Coelho, T., Maia, L.F., Martins da Silva, A., Waddington Cruz, M., Plante-Bordeneuve, V., Lozeron, P., et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79 (2012), 785–792.
47. 47 Epstein, M., Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens Suppl 20 (2002), S17–23.
48. 48 Mukherjee, D., Nissen, S.E., Topol, E.J., Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001), 954–959.
49. 49 Castano, A., Helmke, S., Alvarez, J., Delisle, S., Maurer, M.S., Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 18 (2012), 315–319.
50. 50 Sekijima, Y., Dendle, M.A., Kelly, J.W., Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13 (2006), 236–249.
51. 51 Merlini, G., Plante-Bordeneuve, V., Judge, D.P., Schmidt, H., Obici, L., Perlini, S., et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6 (2013), 1011–1020.
52. 52 Maurer, M.S., Grogan, D.R., Judge, D.P., Mundayat, R., Packman, J., Lombardo, I., et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 8 (2015), 519–526.
53. 53 Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat Mater 12 (2013), 967–977.
54. 54 Hawkins, P.N., Ando, Y., Dispenzeri, A., Gonzalez-Duarte, A., Adams, D., Suhr, O.B., Evolving landscape in the management of transthyretin amyloidosis. Ann Med 47 (2015), 625–638.
55. 55 Ackermann, E.J., Guo, S., Booten, S., Alvarado, L., Benson, M., Hughes, S., et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19:Suppl 1 (2012), 43–44.
56. 56 Cardoso, I., Martins, D., Ribeiro, T., Merlini, G., Saraiva, M.J., Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med, 8, 2010, 74.
57. 57 Mirto, T., Dupee, D., Geller, H., Falk, R.H., Doxycycline and TUDCA combination slow the progression of ATTR amyloid cardiomyopathy in humans. XVth International Symposium on Amyloidosis, 2016 p PA91.
58. 58 Berk, J., Ruberg, F.L., Pawar, S., Brueckner, C.A., Wiesman, J.F., Stern, L., et al. Doxycycline treatment of amyloidosis: a phase II study. The XVth International Symposium on Amyloidosis. Uppsala, Sweden, 2016 p PA110.
59. 59 Richards, D.B., Cookson, L.M., Berges, A.C., Barton, S.V., Lane, T., Ritter, J.M., et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373 (2015), 1106–1114.
60. 60 Penchala, S.C., Connelly, S., Wang, Y., Park, M.S., Zhao, L., Baranczak, A., et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy–associated V122I transthyretin. Proc Natl Acad Sci USA 110 (2013), 9992–9997.
61. 61 Sant'Anna, R., Gallego, P., Robinson, L.Z., Pereira-Henriques, A., Ferreira, N., Pinheiro, F., et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun, 7, 2016, 10787.